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How to Deal with Weak Interactions in Noncovalent Complexes
Analyzed by Electrospray Mass Spectrometry: Cyclopeptidic
Inhibitors of the Nuclear Receptor Coactivator 1-STAT6
Abstract
Mass spectrometry, and especially electrospray ionization, is now an efficient tool to study noncovalent
interactions between proteins and inhibitors. It is used here to study the interaction of some weak
inhibitors with the NCoA-1/STAT6 protein with KD values in the μM range. High signal intensities
corresponding to some nonspecific electrostatic interactions between NCoA-1 and the oppositely
charged inhibitors were observed by nanoelectrospray mass spectrometry, due to the use of high ligand
concentrations. Diverse strategies have already been developed to deal with nonspecific interactions,
such as controlled dissociation in the gas phase, mathematical modeling, or the use of a reference
protein to monitor the appearance of nonspecific complexes. We demonstrate here that this last
methodology, validated only in the case of neutral sugar-protein interactions, i.e., where dipole-dipole
interactions are crucial, is not relevant in the case of strong electrostatic interactions. Thus, we
developed a novel strategy based on half-maximal inhibitory concentration (IC50) measurements in a
competitive assay with readout by nanoelectrospray mass spectrometry. IC50 values determined by MS
were finally converted into dissociation constants that showed very good agreement with values
determined in the liquid phase using a fluorescence polarization assay.
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ABSTRACT: 
Mass spectrometry, and especially electrospray ionization, is now an efficient tool to study non-
covalent interactions between proteins and inhibitors. It is used here to study the interaction of some 
weak inhibitors with the NCoA-1/STAT6 protein with KD values in the μM range. High signal 
intensities corresponding to some nonspecific electrostatic interactions between NCoA-1 and the 
oppositely charged inhibitors were observed by nanoelectrospray mass spectrometry, due to the use 
of high ligand concentrations. Diverse strategies have already been developed to deal with 
nonspecific interactions, such as controlled dissociation in the gas phase, mathematical modeling, or 
the use of a reference protein to monitor the appearance of nonspecific complexes. We demonstrate 
here that this last methodology, validated only in the case of neutral sugar/protein interactions, i.e. 
where dipole-dipole interactions are crucial, is not relevant in the case of strong electrostatic 
interactions. Thus, we developed a novel strategy based on half-maximal inhibitory concentration 
(IC50) measurements in a competitive assay with readout by nanoelectrospray mass spectrometry. 
IC50 values determined by MS were finally converted into dissociation constants that showed very 
good agreement with values determined in the liquid phase using a fluorescence polarization assay. 
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1. Introduction: 
 
There is a strong interest in the study of non-covalent complexes between biomolecules, which are 
playing key roles in life. Numerous solution-phase analytical techniques were developed in order to 
determine the specificity and the strength of these types of interactions [1]. Mass spectrometry (MS), 
and especially electrospray ionization (ESI) [2], has become an efficient tool to study specific non-
covalent complexes between various species (protein-protein, protein-small molecules, protein-
DNA, DNA-DNA …) [38]. In fact, ESI is a very soft ionization technique, i.e. non-covalent 
complexes can be transferred intact from solution into the gas phase. Quantitative information such 
as stoichiometry, binding constants, or reaction kinetics, can be obtained by ESI-MS and values are 
often in good agreement with data coming from well-established solution phase techniques. 
Nevertheless, the study of non-covalent [protein : ligand] complexes requires careful control of 
experimental parameters. Buffer, pH, pressure and voltages applied to the different stages of the 
mass spectrometer have great influence on spectral characteristics and on the information gained. 
Moreover, electrochemical reactions and desolvation/ionization mechanisms involved in ESI can 
also complicate the analysis, thus giving rise to the so-called nonspecific interactions (i.e. 
interactions with nonspecific binding sites) which alter the solution phase stoichiometry. To study 
weak complexes with dissociation constants (KD) in the μM range or higher in solution, high ligand 
concentrations are employed leading to an increase of the  nonspecific gas-phase interactions and to 
underestimate KD values, which could not reflect the solution-phase equilibria anymore [5,9-16].   
Three strategies have been developed to determine affinities of weak [protein : ligand] complexes 
by ESI-MS, even when nonspecific gas-phase interactions unsettle the analysis.  
1. One possibility is to disrupt the nonspecific gas-phase interactions between ligand and protein, 
by using blackbody infrared radiation dissociation (BIRD) [12]. Nonetheless it was shown that, in 
some cases, nonspecific interactions can be even stronger than the specific interactions, leading to 
the destruction of the complex of interest [5].  
2. Daubenfeld et al. have shown that specific ligand binding is modeled as a binomial distribution, 
while complexes resulting from nonspecific gas-phase interactions follow a statistical Poisson 
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distribution [15]. As a consequence, the contributions of specific and nonspecific binding on the 
mass peak distributions could be modeled from the dependence on ligand concentration. This 
method has been successfully used to determine the affinity range of ADP and ATP binding with 
creatine kinase. However, since many numerical parameters of the model have to be adjusted, high 
quality spectra are required and initial knowledge of the specific interactions is required.  
3. Klassen et al. [16] reported a third strategy: a reference protein which is known to not 
specifically bind with the ligand in solution phase is added to the sample mixture consisting of the 
ligand and the target protein. Detection of noncovalent complexes between the ligand and the 
reference protein by nanoESI-MS results only from gas phase interactions. Peak intensities and their 
distribution could be used to model gas phase interactions between the ligand and the target protein. 
The principal assumption is that the distribution of ligand molecules binding nonspecifically to 
proteins during the nanoESI process is determined by the number of free ligand molecules in the 
shrinking nanodroplets: interactions should proceed independently from the size and the structure of 
the protein or the protein complex. 
  
Considering the key role of MS in the drug discovery process, we focused on the development of 
new ESI assays which could be of value to measure the affinity of noncovalent [protein : peptide] 
complexes, even when partial nonspecific interactions are exhibited in the gas phase. As example of 
the methodology, we explore the binding of some cyclopeptides with PAS-B domain of the co-
activator protein NCoA-1 (also called steroid receptor coactivator-1, SRC-1). NCoA-1 is one of the 
essential proteins involved in the Interleukin-4/Interleukin-13 (IL4/IL13) signaling cascade which 
controls the activation of genes implicated in immune and anti-inflammatory responses [17,18]. The 
ability of IL-4 to affect cellular differentiation requires the activation of the signal transducer and 
activator of transcription 6 (STAT6). Following binding of IL-4/IL-13 to the extracellular domain of 
the IL-4/13 receptor, IL-4 becomes phosphorylated, whereupon it dimerizes through non-covalent 
interactions, translocates to the nucleus, and there binds through its DNA-binding domain to the 
transcriptional start regions of IL-4/IL-13 responsive genes. A short C-terminal segment of STAT6, 
called the transactivation domain, recruits components of the transcriptional machinery to activate 
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transcription. One of these components is the coactivator protein NCoA-1 [19]. It has been proposed 
that blocking the binding of STAT6 and NCoA-1 are potentially of therapeutic interest for the 
treatment of allergic reactions, including asthma and atopic diseases [20,21]. In the following report, 
we propose to use a reference peptide with a known KD value for the NCoA-1 PAS-B domain. 
Displacement of the reference peptide from the protein by an inhibitor leads a decrease in the peak 
intensity of the reference protein/peptide complex. As internal standard, a second protein, i.e. 
myoglobin, has been chosen to bind with neither the reference peptide nor the inhibitor in solution as 
well as in the gas phase. After normalization, data are fitted to a sigmoid equation to determine the 
IC50 values from the dependence on inhibitor concentration. Thereafter KD values of the competitive 
inhibitors are extrapolated using a general Cheng-Prusoff equation.  
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2. Material and methods: 
Chemicals: 
Commercial reagents were used without further purification. Myoglobin, lysozyme, lactalbumin, 
ammonium bicarbonate, methanol and acetic acid were purchased from Sigma (Sigma-Aldrich 
Chemie GmbH, Buchs, Switzerland).  
 
Peptide synthesis: 
Peptides (1), (2), and (6) and inhibitors A, B and C (Table 1) were synthesized by solid phase 
methods using standard Fmoc chemistry on an Applied Biosystems 433A peptide synthesizer. The 
backbone-cyclic peptides were assembled on 2-chlorotrityl chloride resin (Novabiochem). The 
synthesis of peptide 1 is described here as a typical procedure. 
 Fmoc-Tyr-OH (0.25 mmol) was coupled to 2-chlorotritylchloride resin (600 mg, loading = 
0.417 mmol/g) in the presence of diisopropylethylamine (DIPEA, 4 eq.) in CH2Cl2 (15 ml) The 
unreacted sites on the resin were capped by washing with a mixture of CH2Cl2/MeOH/DIPEA 
(17:2:1) followed by MeOH. Following removal of the Fmoc-group using 20% piperidine in N-
methyl-2-pyrrolidinone (NMP), chain elongation was performed with Fmoc-Gly-OH, Fmoc-
Ser(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-
Thr(tBu)-OH, Fmoc-Pro-OH, Fmoc-Pro-OH (1 mmol each), using 20% piperidine/NMP for Fmoc 
deprotection, HBTU/HOBt for activation, DIPEA as base and NMP as solvent. After completion of 
the synthesis, the linear peptide was cleaved from the resin and deprotected with 
CF3COOH/water/triisopropylsilane (v/v, 95:2.5:2.5). After removing the solvent, the peptide was 
precipitated with diisopropyl ether (15 ml), collected by centrifugation and washed 2 times with 
diisopropyl ether (15 ml). Purification was performed by preparative HPLC. HPLC analyses were 
performed using a Vydac 218TP54 C18 column (250 x 46 mm; particle size 5 µm; Solvent A: H2O / 
TFA v/v 0.1%; Solvent B: MeCN / TFA v/v 0.1%; flow 1 ml/min; Linear gradient A / B: from 85 / 
15 to 45 / 55 in 25 min). The retention time was estimated to 15.6 min. To confirm the identification, 
MALDI-TOF MS analysis was performed in the positive ion mode, showing an intense peak at m/z 
2401.1, corresponding to the expected monoisotopic mass of the [M+H]+ ion.  
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Stock solutions: each peptide was dissolved in an ammonium bicarbonate (50 mM, pH 7.5) buffer 
to give a 200 µM solution. Concentrations were determined by UV at 280 nm. 
 
Production of NCoA-1 PAS B domain 
NCOA-1 PAS B domain (residues 257-385 of human NCoA-1) was obtained at a concentration of 
30 to 50 µM in HEPES (10 mM), NaCl (150 mM) and EDTA (3.4 mM) pH 7.4 according to the 
protocol reported by Seitz et al. [22]. For Nano-ESI experiments, the protein was dialyzed against an 
ammonium bicarbonate (50 mM, pH 7.5) buffer. 
 
Mass spectrometry 
 Mass spectrometric analysis was performed with a hybrid quadrupole time-of-flight mass 
spectrometer (Q-Tof Ultima; Waters/Micromass Ltd, Manchester, UK) fitted with an automated 
chip-based nanoESI robot (NanoMate Model 100, Advion Bioscience, Ithaca, NY, USA). All 
measurements were performed in the positive ion mode. The cone voltage was kept at 45 V and the 
RF lens 1 at 100 V for all measurements. Argon was used as collision gas and a typical setting of 10 
V was used for the collision energy parameter to optimize desolvation. The transmission of the ions 
through the quadrupole was optimized for the required mass range (m/z 1500–3000). Mass spectra 
were accumulated during 2–3 min to have a good signal-to-noise ratio. Calibration of the instrument 
was performed using 1 µM myoglobin solution in water/methanol/acetic acid (50/50/1, V/V). 
Denaturing conditions were obtained by dissolving the sample in water/methanol/acetic acid 
(50/50/1, V/V), whereas non-denaturing conditions were obtained by using an ammonium 
bicarbonate (50 mM, pH 7.5) buffer.  
 
NanoESI-MS Competition assay  
Assays were carried out in a 96-well microtiter plate. For KD measurement of [NCoA-1 : 
cyclopeptide] complex, each well was loaded with 2 μL of 30 μM NCoA-1 solution, 1 μL of 200 
μM peptide 2 solution, 1 μL of 50 μM myoglobin solution. Peptide 1 (or cyclopeptide) was added at 
a final concentration of 0-10 μM (0-80 μM for cyclopeptide). In each well, the total volume was 
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made up to 10 μL by the addition of ammonium bicarbonate buffer. The plate was incubated at room 
temperature for 5 min prior to the NanoESI-MS analysis. The fraction of NCoA-1 bound to peptide 
(2) is correlated to the peak ratio of [NCoA-1 : peptide (2)] complex (charge state 7) versus 
myoglobin (charge state 8). After normalization, data were fitted with Origin v7.5 software 
(OriginLab Corporation, Northampton, MA USA) to a sigmoid equation for IC50 values 
determination. The KD values were extrapolated from IC50 values according to the method described 
by Nikolovska-Coleska et al. [26] 
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3. Results and discussion: 
In a first approach, we planed to use a reference peptide with a known KD towards NCoA-1. 
Displacement of the reference peptide from the protein by increasing inhibitor concentration should 
lead in a decrease of the peak intensity of the reference [peptide : protein] complex, and the 
apparition of new signals corresponding to the [inhibitor : protein] complex. Since both reference 
and sample peptides are small compared to NCoA-1, we assumed that the ionization of the 
complexes should be essentially governed by the protein. Therefore, the ratio of peak intensities of 
both complexes should correlate the relative affinities of the reference peptide and the inhibitors 
towards NCoA-1. 
 
Selection of peptidic reference ligands  
The interaction between STAT6 and NCoA-1 is mediated by a short section of the STAT6 
transactivation domain that includes the sequence motif LXXLL (L=leucine, X=any amino acid), 
which upon binding to a PAS-B domain of NCoA-1 folds into an amphipathic α-helix [23]. The 
crystal structure of a STAT6-derived peptide (794-814) complexed with NCoA-1 PAS-B domain 
(257-385) with a 1:1 stoeichiometry (PDB file 1OJ5) was reported by Razeto et al [24]. As reference 
ligands for the competition assay, we chose two linear peptides including residues Leu794-Gly814 
(peptide 1) and Leu795-Gly814 (peptide 2) of STAT6. Peptides 1 and 2 have an additional C-terminal 
Tyr to aid concentration measurements by UV. Their affinities for NCoA-1, determined by a 
competitive fluorescence polarization assay and/or isothermal titration calorimetry, have been 
reported to be 0.30 µM and 7.5 µM, respectively (Table-1) [22].  
 
Figure 1 shows a representative spectrum of NCoA-1 in non-denaturing buffer. Two charge state 
distributions are present, probably corresponding to a folded (m/z 1700-3000) and a partially or 
completely unfolded conformation of the protein (m/z 800-1700). It must be noted that the use of a 
denaturing buffer does not change the charge state distribution, i.e. the protein is quite insensitive to 
pH or solvent changes. In a second experiment, NCoA-1 (6 μM) was mixed in ammonium acetate 
buffer (50 mM) with the two peptides (1) (Figure 2A), and (2) (Figure 2B) at a high concentration 
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(60 μM, i.e. a 10-fold excess) compared to the protein concentration. Complexes (1:1 protein:ligand 
stoichiometry) were only observed for the charge states 7 and 8, whereas no complex was observed 
in the m/z 800-1700 range. This confirmed that charge states 6, 7 and 8 correspond to the folded 
active protein, whereas the higher charge states correspond to inactive conformations. In the case of 
peptide (1) (Figure 2A), only a very weak signal at m/z~2800 was found for the 7+ complex that 
correspond to a 1:2 protein:ligand stoichiometry. Since we showed by isothermal titration 
calorimetry (ITC) that peptide (1) binds to NCoA-1 in a 1:1 interaction model [22], we assumed that 
the 7+ complex only results from gas phase interactions due to the high concentration of the ligand. 
This has been confirmed at lower peptide concentration (ratio 1:5 or below) by the disappearance of 
the signal corresponding to the 1:2 protein:ligand stoichiometry complex . 
 
Specific versus nonspecific gas-phase interactions: 
Recently, numerous cyclopeptide competitive inhibitors of STAT6 : NCoA-1 binding were 
developed in Robinson’s group. KD values of the [NCoA-1 : cyclopeptide] complex have been 
measured by a competitive fluorescence polarization assay [22], confirming that, in solution, 
peptides (1) and (2) and all the inhibitors interact with the same binding site on NCoA-1 PAS-B 
domain. Three cyclopeptide competitive inhibitors (A), (B) and (C) have been selected for extended 
experiments. KD values of inhibitors (A), (B) and (C) of NCoA-1 were measured to be 3.0 µM, >40 
µM and 12.1 µM, respectively, by a competitive fluorescence polarization assay [22]. Whatever the 
inhibitor chosen, at 6 μM protein and 60 μM cyclopeptide concentrations, complexes with 1:1, 1:2 
or even 1:3 protein:ligand stoichiometry were observed for charge states 6, 7 and 8, as well for 
charge state 9, which was attributed to an unfolded protein complex (Figures 2C, 2D). These peaks 
did not disappear at lower peptide concentration. We assumed that they result from nonspecific gas-
phase interactions, probably due to direct electrostatic interactions between deprotonated 
carboxylate groups from glutamate residues of the cyclopeptidic inhibitors and some protonated 
basic residues on the protein surface. Since electrostatic interactions are greatly enhanced in the gas 
phase compared to the solution phase (ratio of the dielectric constant of water compared to vacuum) 
[25], nonspecific electrostatic adducts are stabilized. This assumption is first confirmed by the fact 
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that the nonspecific adducts resulting from the aggregation of NCoA-1 with peptide (A) are stable 
even if a collision energy parameter of 80 V (max=120V) is applied. Secondly, the intensity ratio 
between the free protein and the aggregates is charge state dependent (Figure 2 C): the higher the 
charge state, the higher the nonspecific adducts intensity. While fluorescence polarization 
competition assay showed that inhibitor (A) (KI = 3.0 µM) is a tighter binder than peptide (2) (KI = 
7.5μM), we observed that peak intensities of [NCoA-1 : cyclopeptide (A)] complex are lower to 
those of [NCoA-1 : peptide (2)] complex (Figure 3). Therefore, it is clear that without any 
quantification of the nonspecific gas-phase interactions, no direct results on the relative KD can be 
obtained. 
 
In order to estimate the nonspecific binding, we first focused on the methodology developed by 
Klassen et al. [16], consisting on the analysis of noncovalent complexes, which result only from gas-
phase interactions between a ligand and a model protein. The principal assumption is that the peak 
distribution of complex resulting from nonspecific interactions should proceed independently from 
the size and the structure of the protein (NCoA-1 and the model protein). Therefore, we mixed 
inhibitor (B) (60 µM) with 3 different reference model proteins (myoglobin, lactalbumin or 
lysozyme at 6 µM final concentration). Inhibitor (B) was chosen as a test compound because of its 
very low affinity for NCoA-1 (KD>40 μM determined by fluorescence polarization) in solution. 
Figure 4 shows the results obtained for myoglobin, lactalbumin and lysozyme (Figures 4A, B, and 
C, respectively). For myoglobin (MW~17600 Da) and lactalbumin (MW~14200 Da), nonspecific 
complexes were observed for the highest charge state, i.e. 8 and 7, respectively. Moreover, the 
intensity ratio between the free and the bound fraction of protein was 10:1 for myoglobin but only 
3.5:1 for lactalbumin. For lysozyme (MW~14300 Da), which has a molecular weight similar to that 
of lactalbumin but a completely different amino acid sequence, nonspecific complexes were 
observed for the charge states 8 and 7. For the charge state 8, we observed one or two molecules of 
(B) binding to the protein, whereas only a complex with a 1:1 stoichiometry was detected for the 
charge state 7. Thus, for all reference proteins, as well for NCoA-1, a charge state dependence of the 
peak intensities of the nonspecific complexes exists. Our observations suggest that the stability of 
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the nonspecific complexes is related to the structure of the protein, which means that the main 
assumption of Klassen et al. is not valid. Klassen’s method was developed and validated with 
protein:sugar complexes. Sugars are neutral components and the possible noncovalent interactions 
with a binding partner should only involve dipole interactions. However for cyclopeptide (B), we 
have strong evidence that electrostatic forces are involved in the nonspecific gas-phase interactions 
with proteins, which apparently creates quite a different situation.  
 
Competition assay using myoglobin as internal standard: 
To measure affinities of some noncovalent [NCoA-1 : cyclopeptide] complexes, even when 
ligands form nonspecific gas-phase interaction with the protein, we focused on a new competition 
assay consisting on the analysis of the peak intensity of the reference [NCoA-1 : peptide (2)] 
complex. Since the linear peptide (2) (KD=7.5 µM) does not exhibit any nonspecific interaction with 
NCoA-1, even at high concentration, we decided to use it as reference ligand. Intensities are 
calibrated with the signal of myoglobin, used as internal standard. Myoglobin have been chosen 
because of its very low affinity in solution as well in gas phase, for peptide (2) and for 
cyclopeptides. Its concentration was fixed to 5 μM. Therefore, since formation of nonspecific 
complexes with myoglobin is very limited, the peak intensity ratio between [NCoA-1 : peptide (2)] 
complex and myoglobin should be linearly correlated to the fraction of NCoA-1 bound to peptide 
(2). In a competition assay, displacement of the peptide (2) from NCoA-1 by any inhibitor should 
result in a decrease of this ratio. The concentration (IC50) of the inhibitor which is required for 50% 
displacement of peptide (2) from NCoA-1, could be determined from the dependence of this ratio on 
inhibitor concentration. Finally, the dissociation constant (KD) of the [NCoA-1 : cyclopeptide] 
complex could be calculated from the IC50 values using the general Cheng-Prusoff equation 
described by Nikolovska-Coleska [26]. 
 
Validation of the method was first performed on linear peptide (1) as inhibitor, which did not 
show any nonspecific interaction with NCoA-1. The concentrations of peptide (2), NCoA-1 and 
myoglobin were fixed at 20 µM, 6 µM and 5 µM, respectively. Figure 5 shows the spectra obtained 
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at different concentrations of peptide (1) (from 0 to 10 µM). Whatever peptide (1) concentration, 
myoglobin didn’t exhibit any nonspecific interactions with peptide (1) and / or peptide (2). Since the 
peak intensity corresponding to the charge state 8+ of myoglobin remained similar for all samples, 
the fraction of NCoA-1 bound to peptide (2) was correlated to the peak ratio of [NCoA-1 : peptide 
(2)] complex (charge state 7) versus myoglobine (charge state 8+). After normalization, data was 
plotted versus the logarithm of peptide (1) concentration and fitted to a sigmoid equation to 
determine the IC50 value (IC50 = 4.2 μM) (Figure 6A). KD calculated, from IC50 value was 299±20 
nM, which is very close to the KD value obtained by fluorescence polarization (KD=260 nM) [22].  
 
We then tested our methodology on inhibitors (A), (B) and (C). The concentrations of peptide (2), 
NCoA-1 and myoglobin were fixed at 20 µM, 6 µM and 5 µM, respectively. Each cyclopeptide gave 
some adducts with NCoA-1 in 1:1 and 1:2 protein:ligand stoichiometries (Figure 7). Nevertheless, 
whatever cyclopeptide concentrations (0 to 40 µM), any nonspecific interactions with myoglobin 
and [NCoA-1:peptide (2)] complex were detected. Thus, the fraction of NCoA-1 bound to peptide 2 
was correlated to the peak ratio of [NCoA-1 : peptide (2)] complex versus myoglobine. After data 
normalization and fitting to a sigmoidal equation, IC50 values (Figure 8) of inhibitors (A) and (C) 
were estimated to 11.3 μM and 23.5 μM, corresponding to KD values of 2.2 μM and 5.6 μM, 
respectively. These values are in good agreement with fluorescence polarization measurements (KD 
= 3 μM and 12.1 μM, respectively). For inhibitor B, we also confirmed its low affinity for NCoA-1 
(KD > 20 μM). 
 
By using peptide (2) as reference compound, we were able to determine KD values from 0.1 to 20 
µM that showed a very good correlation with liquid phase measurements. However for a stronger 
ligand, another reference compound would have to be chosen. In order to extend the affinity range 
that we can measure, we propose to use peptide (1) (KD = 299 nM) as reference peptide. Validation 
of this new probe was done with the N-acetylated linear peptide (6) that includes residues Gly783-
Gly814 of STAT6, as competitor. The concentrations of peptide (1), NCoA-1 and myoglobin were 
fixed at 20 µM, 6 µM and 5 µM, respectively. After data normalization and fitting to a sigmoid 
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equation (Figure 6B), the IC50 values of peptide (6) was estimated to be 4 μM, corresponding to a 
KD of 17nM, which is again in good agreement with reported fluorescence polarization data (KD~40 
nM) [22]. It must be noted that such low KD values that are lower than 2-3 orders of magnitude of 
the concentrations used in experiments, are usually difficult or impossible to measure by direct 
titration using nanoESI-MS [27]. 
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4. Conclusion: 
The potential of mass spectrometry for direct analysis of complex biological samples has been 
extensively demonstrated. In particular, because of its high sensitivity and selectivity, nano-ESI MS 
becomes a real alternative for quantitative analysis and monitoring [protein : ligand] binding. 
However, the study of protein-ligand non-covalent complexes requires careful control of 
experimental parameters since desolvation/ionization mechanisms involved in ESI can complicate 
the analysis. We reported in the present study a new nano-ESI MS competition assay which is of 
value to determine the affinity of weak protein-ligand complexes, even when nonspecific 
electrostatic interactions are exhibited in gas-phase. The measurement of KD values, in good 
agreement with results obtained by an independent Fluorescence Polarization assay, confirm that 
when the reference ligand and the internal standard are properly selected, the method can be 
implemented for many different types of non-covalent complexes. Finally, automation of sample 
preparations and data acquisition should allow to access to a medium or even high-throughput 
screening assay to find inhibitor of [protein : protein] interaction. 
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Table 1 
Sequences 
Monoisotopic 
mass (Da) 
KI obtained by 
fluorescence 
polarization 
assay (μM)[22] 
KI 
obtained 
here (μM)
(1) LLPPTEQDLTKLLLEGQGESGY 2400.2 0.26 0.30 
(2) LPPTEQDLTKLLLEGQGESGY 2287.2 7.5 
used as 
reference 
Inhibitor A: cyclic-FEWLGWEFpP 1288.5 3.0 2.2 
Inhibitor B: cyclic-FEWLAREFpP 1272.6 >20 >20 
Inhibitor C: cyclic-FEWLLWEFpP 1318.5 12.1 5.6 
(6) Ac-GTWIGEDIFPPLLPPTEQDLTKLLLEGQGESG 3491.2 0.040 0.017 
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FIGURE CAPTIONS: 
Table 1. Monoisotopic masses and KD values obtained by fluorescence polarization assay and by 
mass spectrometry for the STAT6-derived peptides.  
 
Figure 1. NanoESI mass spectrum of NCoA-1 at a 5μM concentration in a non-denaturing buffer 
(ammonium bicarbonate, 50 mM, pH 7.5). 
 
Figure 2. NanoESI mass spectra of the non-covalent complexes between NCoA-1 (6 μM) and (A) 
peptide (1) (60 μM), (B) peptide (2) (60 μM), (C) peptide (A) (60 μM) and (D) peptide (B) (60 μM). 
Symbol ■ corresponds to the ligand.  
 
Figure 3. NanoESI spectrum of the non-covalent complexes between NCoA-1 (6 μM), peptide (A) 
(20 μM) and peptide (2) (20 μM). Symbols ◄and ■ correspond to the peptides (A) and (2), 
respectively.  
 
Figure 4. NanoESI spectra of the nonspecific non-covalent complexes between (A) myoglobin (6 
μM), (B) lactalbumin (6 μM) or (C) lysozyme (6 μM) and peptide (B) (60 μM). Symbol ■ 
corresponds to the ligand. 
 
Figure 5. NanoESI spectra obtained for the competitive binding assay using the non-covalent 
complex NCoA-1(6 μM):peptide (2) (20 μM) as probe and increasing concentration of peptide (1) 
(0-10 μM). Myoglobin at a 5 μM concentration is used as internal standard. Symbols ◄ and ■ 
correspond to the peptide (2) and peptide (1), respectively. 
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Figure 6. Displacement (A) of NCoA-1:peptide (2) probe from NCoA-1 by peptide (1) peptide; (B) 
and of NCoA-1:peptide (1) probe from NCoA-1 by peptide (6). 
 
Figure 7. NanoESI spectra obtained for the competitive binding assay using the non-covalent 
complex NCoA-1(6 μM):peptide (2) (20 μM) as probe and increasing concentration of inhibitor (A) 
(0-40 μM).  Myoglobin at a 5 μM concentration is used as internal standard. Symbols ◄ and ■ 
correspond to the peptide (2) and inhibitor (A), respectively. 
 
Figure 8. Displacement of NCoA-1: peptide (2) probe from NCoA-1 by (A) peptide (A) or (B) 
peptide (C). . 
 
 
 
